![Yi Jun Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Yi Jun Lu is currently the General Manager at CANbridge Pharmaceuticals Inc. Prior to this, he worked as the Head of Hemophilia & Rare Disease at Takeda (China) Holdings Co. Ltd. for a brief period in 2020 and as the Head of Hematology at Shire Bioscience (Shanghai) Co., Ltd. from 2018 to 2019.
Actieve functies van Yi Jun Lu
| Bedrijven | Functie | Begin |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Corporate Officer/Principal | 09-11-2020 |
Eerdere bekende functies van Yi Jun Lu
| Bedrijven | Functie | Einde |
|---|---|---|
Takeda (China) Holdings Co. Ltd. | Corporate Officer/Principal | 01-11-2020 |
Shire Bioscience (Shanghai) Co., Ltd. | Corporate Officer/Principal | 01-04-2019 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Takeda (China) Holdings Co. Ltd. | |
Shire Bioscience (Shanghai) Co., Ltd. | |
CANbridge Pharmaceuticals Inc.
 CANbridge Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
